A new blood test measuring p-tau217 protein can roughly predict Alzheimer's symptom onset, rising consistently before memory loss. Promising for early treatment, current models have limitations regarding range and participant diversity. Future research aims to improve accuracy.
A 20-year NIH-funded randomized trial found "speed of processing" cognitive training significantly reduced dementia risk by 25% in older adults, including Alzheimer's, making it the only intervention to show such long-term protective effects.
New research suggests low-dose THC combined with an anti-inflammatory medicine could protect memory and reduce mental retardation in Alzheimer's, a disease affecting millions and previously resistant to COX-2 preventions, offering a faster potential therapy.
Johns Hopkins researchers discovered nanotubes in brain cells that transport toxins, including amyloid-beta related to Alzheimer's. Controlling these nanotubes could offer a future treatment.
Research links microplastic exposure to cognitive decline and Alzheimer's, especially in those with the APOE4 gene. Sex-dependent behavior changes observed in mice mirror human Alzheimer's patients.
Alzheimer's research is at a critical point with initial therapies emerging, but more efficient drugs are needed. Research focuses on early treatments, inflammation's role, and overcoming funding challenges. Biomarkers are vital.
Researchers identify cancer drugs (Letrozole, Irinotecan) that may reverse Alzheimer's brain changes by targeting gene expression. Combination therapy shows promise in mouse model, paving way for clinical trials.
High insulin resistance (TyG index) may flag early Alzheimer's patients at 4x greater risk of rapid cognitive decline, offering new treatment possibilities. Metabolic stress is key.
